의학서적전문 "성보의학서적"의 신간도서입니다.

Part of the renowned Braunwald family of references, Clinical Lipidology: A Companion to Braunwald’s Heart Disease provides today’s clinicians with clear, authoritative guidance on the therapeutic management of patients with high cholesterol levels and other atherogenic lipid disorders. An invaluable resource for cardiologists, lipidologists, endocrinologists, and internal medicine physicians, this one-stop reference covers everything from basic science and the pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options. Now fully updated from cover to cover, the 3rd Edition offers unparalleled coverage of lipidology in an accessible and user-friendly manner.

Key Features

Thoroughly covers the assessment, diagnosis, and treatment of patients with elevated levels of lipids and lipoproteins, including all the latest research-based recommendations, therapeutic breakthroughs, and related clinical advances.
Presents the latest data on clinical guidelines, risk assessments, and established and emerging pharmacologic and nonpharmacologic therapies—all from internationally recognized experts in the field.
Features condensed, streamlined content that focuses on clinical applications and applying concepts to the practice setting. Chapters have now been completely reorganized into sections on risk assessment; therapy; new and evolving therapeutic targets and platforms; and special populations.
Includes new chapters on Polygenic Risk Scores; Inclisiran; Bempedoic Acid; Selective Peroxisome Proliferator–Activated Receptor–a Modulator: Pemafibrate; Evolving Therapeutic Targets: Lp(a), ANGPTL3, and ApoC-III; New Therapeutic Platforms: Gene Therapy and Genome Editing; and more.
Contains new or expanded content on inflammation; genetic testing; troponins for risk assessment; statins and role of bile acid sequestrants, niacin, and fibrates; mAbs; CANTOS and CIRT; colchicine; IL-6; and cellular, molecular, and genetic therapy.
Provides treatment algorithms throughout, as well as case vignettes that highlight the most common clinical questions in each chapter.
Incorporates the latest guidelines from the AHA, ACC, ESC, and EAS, as well as future directions for ongoing research and emerging applications.
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

-도서목차-

Section 1 Basic Mechanisms

1. Human Plasma Lipoprotien Metabolism
2. Regulation and Clearance of Apolipoprotein B–Containing Lipoproteins
3. Absorption and Excretion of Intestinal Cholesterol and Other Sterols
4. High-Density Lipoprotein Metabolism
5. Lipoproteins: Mechanisms for Atherogenesis and Progression of Atherothrombotic Disease
6. Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism
7. Lipoprotein Oxidation: Mechanisms and Biotheranostic Applications

Section 2 Risk Assessment

8. Cholesterol: Concentration, Ratio, and Particle Number
9. High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment
10. Lipoprotein(a)
11. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia
12. Use of High Sensitivity C-Reactive Protein for Risk Assessment
13. Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease
14. Emerging Assays
15. Imaging Atherosclerosis for Risk Stratification by Cardiac Computed Tomography or Carotid Ultrasound

Section 3 Therapy

16. Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol
17. Treatment Guidelines Overview
18. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease
19. Exercise and Lipids
20. Weight Loss
21. Statins
22. Bile Acid Sequestrants
23. Cholesterol Absorption Inhibitors
24. Niacin (Nicotinic Acid)
25. Fibrates
26. Omega-3 Fatty Acids
27. Combination Therapy for Dyslipidemia
28. Nutriceuticals and Functional Foods for Cholesterol Reduction
29. Evolving Targets of Therapy: Cholesteryl Ester Transfer Protein Inhibition
30. Evolving Targets of Therapy: Proprotein Convertase Subtilisin/Kexin 9 Inhibition
31. Evolving Targets of Therapy: Inflammation as a Method to Predict and Prevent Cardiovascular Events
32. Invasive Imaging Modalities and Atherosclerosis: Intravascular Ultrasound
33. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound
34. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Magnetic Resonance Imaging and Positron Emission Tomography Imaging
35. Special Patient Populations: Diabetes and Metabolic Syndrome
36. Special Patient Populations: Women and Elderly
37. Special Patient Populations: Children and Adolescents
38. Special Patient Populations: Familial Hypercholesterolemia and other Severe Hypercholesterolemias
39. Special Patient Populations: Acute Coronary Syndromes
40. Special Patient Populations: Transplant Recipients
41. Special Patient Populations: Chronic Kidney Disease
42. Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups
43. Special Patient Populations: Human Immunodeficiency Patients
44. Therapeutic Targeting of High-Density Lipoprotein Metabolism


기타 도서와 관련된 문의사항은 고객센터(02-854-2738) 또는 저희 성보의학서적 홈페이지내 도서문의 게시판에 문의바랍니다.
감사합니다.
성보의학서적 "http://www.medcore.kr